secwatch.observer — SEC 8-K summary
======================================

Issuer:     bioAffinity Technologies, Inc. (BIAF)
CIK:        0001712762
Form:       8-K
Filed at:   2025-09-09T23:59:59+00:00
Accession:  0001641172-25-026971
Event type: other_material
Sentiment:  positive
Materiality: 0.40
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

bioAffinity Technologies case study shows CyPath Lung detects cancer in ground-glass nodules
--------------------------------------------------------------------------------

- Case study: 66-year-old former smoker with 13mm ground-glass nodule; CyPath Lung returned 'likely malignant' result.
- Robotic bronchoscopy confirmed lung cancer after positive CyPath result; patient referred for surgical treatment.
- Current guidelines recommend 2-5 years watchful waiting; CyPath may reduce diagnostic delay and uncertainty.
- Company issued press release on September 9, 2025 highlighting real-world clinical utility of CyPath Lung.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1712762/000164117225026971/0001641172-25-026971-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1712762/000164117225026971/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-026971

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer